Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab

Rajkumar Venkatramani, Marcio Malogolowkin, Leo Mascarenhas

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

As most active chemotherapy agents against Wilms tumor are incorporated into upfront therapy, particularly for those patients with high risk for recurrence, novel regimens are needed to treat children with relapsed Wilms tumor. We describe four consecutive patients with multiply relapsed Wilms tumor who were treated with a combination of vincristine, irinotecan, temozolomide, and bevacizumab. Two had a complete response, and two had a partial response to treatment. Hematological toxicity and diarrhea were the main side effects. This regimen has activity in patients with multiply relapsed Wilms tumor without excessive toxicity, and should be evaluated further in this setting. Pediatr Blood Cancer 2014;61:756-759.

Original languageEnglish (US)
Pages (from-to)756-759
Number of pages4
JournalPediatric Blood and Cancer
Volume61
Issue number4
DOIs
StatePublished - Apr 1 2014
Externally publishedYes

Fingerprint

irinotecan
temozolomide
Wilms Tumor
Vincristine
Therapeutics
Diarrhea
Recurrence
Drug Therapy
Bevacizumab

Keywords

  • Bevacizumab
  • Chemotherapy
  • Irinotecan
  • Relapse
  • Temozolomide
  • Vincristine
  • Wilms tumor

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. / Venkatramani, Rajkumar; Malogolowkin, Marcio; Mascarenhas, Leo.

In: Pediatric Blood and Cancer, Vol. 61, No. 4, 01.04.2014, p. 756-759.

Research output: Contribution to journalArticle

@article{6b4ded0792224fb4ad79d55917ff9457,
title = "Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab",
abstract = "As most active chemotherapy agents against Wilms tumor are incorporated into upfront therapy, particularly for those patients with high risk for recurrence, novel regimens are needed to treat children with relapsed Wilms tumor. We describe four consecutive patients with multiply relapsed Wilms tumor who were treated with a combination of vincristine, irinotecan, temozolomide, and bevacizumab. Two had a complete response, and two had a partial response to treatment. Hematological toxicity and diarrhea were the main side effects. This regimen has activity in patients with multiply relapsed Wilms tumor without excessive toxicity, and should be evaluated further in this setting. Pediatr Blood Cancer 2014;61:756-759.",
keywords = "Bevacizumab, Chemotherapy, Irinotecan, Relapse, Temozolomide, Vincristine, Wilms tumor",
author = "Rajkumar Venkatramani and Marcio Malogolowkin and Leo Mascarenhas",
year = "2014",
month = "4",
day = "1",
doi = "10.1002/pbc.24785",
language = "English (US)",
volume = "61",
pages = "756--759",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab

AU - Venkatramani, Rajkumar

AU - Malogolowkin, Marcio

AU - Mascarenhas, Leo

PY - 2014/4/1

Y1 - 2014/4/1

N2 - As most active chemotherapy agents against Wilms tumor are incorporated into upfront therapy, particularly for those patients with high risk for recurrence, novel regimens are needed to treat children with relapsed Wilms tumor. We describe four consecutive patients with multiply relapsed Wilms tumor who were treated with a combination of vincristine, irinotecan, temozolomide, and bevacizumab. Two had a complete response, and two had a partial response to treatment. Hematological toxicity and diarrhea were the main side effects. This regimen has activity in patients with multiply relapsed Wilms tumor without excessive toxicity, and should be evaluated further in this setting. Pediatr Blood Cancer 2014;61:756-759.

AB - As most active chemotherapy agents against Wilms tumor are incorporated into upfront therapy, particularly for those patients with high risk for recurrence, novel regimens are needed to treat children with relapsed Wilms tumor. We describe four consecutive patients with multiply relapsed Wilms tumor who were treated with a combination of vincristine, irinotecan, temozolomide, and bevacizumab. Two had a complete response, and two had a partial response to treatment. Hematological toxicity and diarrhea were the main side effects. This regimen has activity in patients with multiply relapsed Wilms tumor without excessive toxicity, and should be evaluated further in this setting. Pediatr Blood Cancer 2014;61:756-759.

KW - Bevacizumab

KW - Chemotherapy

KW - Irinotecan

KW - Relapse

KW - Temozolomide

KW - Vincristine

KW - Wilms tumor

UR - http://www.scopus.com/inward/record.url?scp=84893463503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893463503&partnerID=8YFLogxK

U2 - 10.1002/pbc.24785

DO - 10.1002/pbc.24785

M3 - Article

C2 - 24115645

AN - SCOPUS:84893463503

VL - 61

SP - 756

EP - 759

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -